GU Cancers 2024 | ASCO GU 2024 highlights: BRCAAway, CONTACT-2 and KEYNOTE-564

Benjamin Maughan, MD, PharmD, University of Utah, Salt Lake City, UT, provides his highlights from the ASCO GU Cancers Symposium 2024, including findings from the BRCAAway (NCT03012321) and CONTACT-2 (NCT04446117) trials, where the latter trial assessed cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Dr Maughan additionally discusses trials assessing pembrolizumab and cabozantinib in bladder cancer, and their potential role within the treatment landscape with the advent of enfortumab vedotin and pembrolizumab. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.